Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now
Agenus (AGEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript
Agenus Inc. (NASDAQ:AGEN ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations, Corporate Development Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President, Finance and Principal Financial and Accounting Officer Steven O'Day - Chief Medical Officer Robin Taylor - Chief Commercial Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
Agenus (AGEN) came out with a quarterly loss of $2.04 per share versus the Zacks Consensus Estimate of a loss of $2.36. This compares to loss of $2.60 per share a year ago.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Agenus (AGEN) Is Attractively Priced Despite Fast-paced Momentum
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Are Medical Stocks Lagging Agenus (AGEN) This Year?
Here is how Agenus (AGEN) and Concentra Group (CON) have performed compared to their sector so far this year.
What Makes Agenus (AGEN) a New Buy Stock
Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Here is how Agenus (AGEN) and Abbott (ABT) have performed compared to their sector so far this year.
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Agenus (AGEN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Agenus (AGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround
Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
